I Varthalitis1, M Aoun, D Daneau, F Meunier. 1. Service de Médecine Interne, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium.
Abstract
BACKGROUND: The incidence of Pneumocystis carinii pneumonia (PCP) is increasing in patients with cancer. Possible nosocomial transmission from patients with acquired immune deficiency syndrome to those with cancer has been advocated. METHODS: Retrospectively, 17 patients with cancer were reviewed who had 20 PCP episodes that occurred during a 3-year period (1988-1990). RESULTS: Twelve patients had a hematologic malignant lesion, and five had a solid tumor as their underlying disease. Cytotoxic and/or immunosuppressive drugs were used in 16 patients (94%). The clinical presentation varied from fulminant to inapparent pneumonia. Clinical improvement and survival after appropriate therapy occurred in 12 patients (70%), whereas the remaining 5 patients died within 4 weeks of trimethoprim-sulfamethoxazole treatment initiation. In two patients, pentamidine was substituted. Complications of treatment occurred in six patients (35%). When survivors were compared with nonsurvivors, there was no difference in mean age, leukocyte counts, arterial oxygen tension, or duration of symptoms before treatment. CONCLUSIONS: In this series, nosocomial transmission of PCP was unlikely. Prophylaxis after a first episode of PCP should be considered in patients who will remain immunosuppressed.
BACKGROUND: The incidence of Pneumocystis carinii pneumonia (PCP) is increasing in patients with cancer. Possible nosocomial transmission from patients with acquired immune deficiency syndrome to those with cancer has been advocated. METHODS: Retrospectively, 17 patients with cancer were reviewed who had 20 PCP episodes that occurred during a 3-year period (1988-1990). RESULTS: Twelve patients had a hematologic malignant lesion, and five had a solid tumor as their underlying disease. Cytotoxic and/or immunosuppressive drugs were used in 16 patients (94%). The clinical presentation varied from fulminant to inapparent pneumonia. Clinical improvement and survival after appropriate therapy occurred in 12 patients (70%), whereas the remaining 5 patients died within 4 weeks of trimethoprim-sulfamethoxazole treatment initiation. In two patients, pentamidine was substituted. Complications of treatment occurred in six patients (35%). When survivors were compared with nonsurvivors, there was no difference in mean age, leukocyte counts, arterial oxygen tension, or duration of symptoms before treatment. CONCLUSIONS: In this series, nosocomial transmission of PCP was unlikely. Prophylaxis after a first episode of PCP should be considered in patients who will remain immunosuppressed.
Authors: J van der Lelie; D Venema; E J Kuijper; R P van Steenwijk; M H van Oers; L L Thomas; A E von dem Borne Journal: Infection Date: 1997 Mar-Apr Impact factor: 3.553
Authors: H A Torres; R F Chemaly; R Storey; E A Aguilera; G M Nogueras; A Safdar; K V I Rolston; I I Raad; D P Kontoyiannis Journal: Eur J Clin Microbiol Infect Dis Date: 2006-06 Impact factor: 3.267
Authors: M Chabé; E Dei-Cas; C Creusy; L Fleurisse; N Respaldiza; D Camus; I Durand-Joly Journal: Eur J Clin Microbiol Infect Dis Date: 2004-01-08 Impact factor: 3.267
Authors: Alan K L Wu; Vincent C C Cheng; Bone S F Tang; Ivan F N Hung; Rodney A Lee; David S Hui; Kwok Y Yuen Journal: BMC Infect Dis Date: 2004-12-09 Impact factor: 3.090
Authors: Francisco J Medrano; Marco Montes-Cano; Manuel Conde; Carmen de la Horra; Nieves Respaldiza; Antonia Gasch; Maria J Perez-Lozano; Jose M Varela; Enrique J Calderon Journal: Emerg Infect Dis Date: 2005-02 Impact factor: 6.883